Complex Peripheral Vascular Interventions

Overview

	Sahil A. Parikh, MD, FSCAI Moderator and Speaker		Jon C. George, MD, FSCAI Speaker
	Jun Li, MD, FSCAI Speaker		Marco Manzi, MD Speaker
	Fadi A. Saab, MD, FSCAI Speaker		Sanjum S. Sethi, MD, MPH, FSCAI Speaker
	John Winscott, MD Speaker

Lesion Preparation for SFA Disease: When Do I Use IVL, Atherectomy, BOTH? John Winscott, MD

New Technology Updates in SFA: Has Anything Changed My Approach to CTOs? Sanjum S. Sethi, MD, MPH, FSCAI

SFA Treatment Algorithm: Do We Have It Figured Out Yet? What Don't We Have in Our Toolbox? Jon C. George, MD, FSCAI

BTK Scaffolds: Have DRS Changed Our Approach or Has the Fad Worn Off? Sahil A. Parikh, MD, FSCAI

Deep Vein Arterialization: TIps and Tricks, Fadi A. Saab, MD, FSCAI

Comples Limb Salvage Interventions: Best and Toughest Cases of the Year, Marco Mazi, MD

Searching for the Holy Grail: What's the Right Amount of Perfusion for the Ischemic Limb? Jun Li, MD, FSCAI

Discussion: What is the Most Exciting Innovation in BTK Intervention that is on the Horizon?

Acknowledgment of Commercial Support

This activity is supported by unrestricted educational grants from Boston Scientific, Abbott, Cook Medical, Shockwave Medical and Terumo Medical.

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Synthesize contemporary data into endovascular device selection and decision making for SFA and BTK interventions

2. Review new clinical trial data in both SFA and BTK territories which have changed practice

3. Assess unmet needs and new solutions in interventional techniques to enhance outcomes

4. Discuss the next generation of investigational technologies currently being evaluated for SFA and BTK/CLTI interventions

Disclosures

PLANNER

Sahil A. Parikh: Medtronic - Advisory Board; Inari - Consulting; Cordis - Advisory Board; Terumo - Consulting; Penumbra - Consulting; Abiomed - Consulting; Boston Scientific, Corp. - Advisory Board; Philips - Advisory Board.

FACULTY

Sahil A. Parikh: Medtronic - Advisory Board; Inari - Consulting; Cordis - Advisory Board; Terumo - Consulting; Penumbra - Consulting; Abiomed - Consulting; Boston Scientific, Corp. - Advisory Board; Philips - Advisory Board.

Jon George: Abbott - Consulting; Boston Scientific Corp. - Consulting; Medtronic - Consulting; Philips - Consulting.

Jun Li: Abbott - Consulting; Bostonc Scientific Corp. - Consulting; Medtronic - Consulting.

Marco Manzi: Micromedical Solutions - PI.

Fadi A. Saab: Philips - Speaker; Abbott - Speaker; Reflow Medical - Patent Holder, Speaker.

Sanjum S. Sethi: Boston Scientific - Advisory Board, Consulting; Terumo - Consulting; Penumbra - Consulting; Argon - Consulting; Chiesi - Speaker; Janssen - Speaker; Inari - Consulting.

John Winscott: Medtronic - Advisory Board, Consulting, Speaker; J&J/Shockwave - Advisory Board, Speaker.

REVIEWER

Andrew Klein: No financial relationships with ineligible companies.

SCAI STAFF

Robert Bartel and Laura Porter: No financial relationships with ineligible companies.

Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
SCAI designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Record date: May 2, 2025
Publish date: June 30, 2025
Retire date: April 17, 2026

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Summary

Availability:

On-Demand

Access expires on Apr 17, 2026

Cost:

FREE

Credit Offered:

1.5 CME Credits

1.5 ABIM-MOC Points

1.5 Participation Credits